EQ - Company ID 0001746466
Equillium, Inc. trades as EQ. This page tracks Equillium, Inc. through 444 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Next research step
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Net profit margin expanded from -396.1% to -19.6% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-27 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| SCHEDULE 13G | - | 2026-05-07 |
| EFFECT | - | 2026-04-16 |
| Annual report to shareholders | ARS | 2026-04-15 |
The largest companies sharing Equillium, Inc.'s SEC industry classification (pharmaceutical preparations).
In its latest fiscal year Equillium, Inc. reported a net loss of $22.40M.